PARP1 and prostate carcinoma: In this article, we will review the scientific rationale, preclinical and early clinical data, and future possibilities of one such approach that combines AR and poly (ADP-ribose) polymerase (PARP) inhibition to induce synthetic lethality in prostate cancer cells.